Organ Regeneration Platform



ROKIT Healthcare

Xia Park

Global Business Development Director

History of ROKIT Healthcare

"Beyond Lab to LIFE"

World's First

In-Hospital 4D Organ Regenerator



2012
ROKIT, INC Established

2016
Launched world's first clean-bench 3D bioprinter ROKIT INVIVO
Began R&D of autologous regenerative therapeutics utilizing 3D biofabrication technology

2017
Established ROKIT EU in Germany
Fraunhofer IBMT
Established research MoU with Fraunhofer-Institut für Biomedizinische Technik (IBMT) for therapy development of retina and heart patch

2018
Several research development MOUs with renowned domestic plastic surgical clinics/hospitals
GNG PLASTIC SURGERY GNG HOSPITAL
IDEA Clinic

2018. 7
Mirae Asset Daewoo Securities appointed as the IPO underwriter MIRAE ASSET Mirae Asset Daewoo

2018. 9
ROKIT HEALTHCARE, INC Established
ROKIT HEALTHCARE

2018. 11
ROKIT's first proprietary MA-ECM therapy developed & first clinical study presented at the international plastic surgery conference ISAPS

2019

2019. 03
Cartilage regeneration pre-clinical study presented at AAOS

2019. 10
ISO13485 Medical Devices Certification
In-Hospital 4D Organ Regenerator launched
Dr. INVIVO 4D6

Global Organ Regeneration Clinical Studies
2019. 07 ~ 12

- **Skin Regeneration in Diabetic Foot Ulcers:**
  - India: Hycare Speciality Hospital (Completed)
  - Korea: Korea University (2019.11)
  - Turkey: Acibadem Labcell (2019)
- **Cartilage Regeneration:**
  - USA: MGH Pre-Clinical (2019.10)
  - Egypt: Assiut University (2019)

MGH 1811 · KOREA UNIVERSITY 1905 · HYCARE Super Speciality Hospital · ACIBADEM LABCELL · CLINICA SAN CARLO

World-Class Leadership

ROKIT HEALTHCARE

Chairman & Chief Executive Officer



You, Seok Hwan MBA
CEO / Chairman

- 30+ years of executive management experience
- Comprehensive and keen understanding of the life sciences industry
- Former CEO of **CELLTRION HEALTHCARE** (KOSDAQ: 091990)
- Former Chief Vice President of **TYCO INTERNATIONAL** (APAC regional head)
- Youngest former Executive Director and Chief Operating Officer of **GM DAEWOO** (@EU HQ in Poland)

(i.e.)	CELLTRION HEALTHCARE	SAMSUNG BIOLOGICS
Market Cap	**$25.3 B**	$25.4 B
Stock	**$200 / share**	$350 / share

Scientific Advisory Board



Yoo, J. James MD, PhD
Scientific Advisor



Lee, Jae Ho, MD, PhD
Chief Medical Officer



Choi, Eui Joo PhD
Scientific Advisor



Ryu, Dong Ryul PhD
Scientific Advisor



Han, Seung Gyu MD, PhD
Korea University Hospital
Reconstructive Surgery



Kim, Suh Whan MD, PhD
The Catholic University Korea Seoul St. Mary's Hospital / Otolaryngology



Son, Yong Sook PhD
Scientific Advisor



Kook, Kwang Sik MD, PhD
IDEA Plastic Surgery
Plastic Surgery



Jang, Dae Ik MD, PhD
Seoul National University
Plastic Surgery /
Evolutionary Biology

Management & Leadership

Chief Operations




Hong, Sung Joon
COO, CPA, AICPA
Member of New York Bar Board

Biomedical R&D



Lee, Youn Soo, PhD
President, CTO
Biomedical R&D



Kim Jae Yoon, PhD
President
SBU of Humatein, Bioink



Kim Jee Hee, PhD
President
SBU of DFU, Skin Regeneration



Jeong, Hyun Woo, PhD
Director
Biomedical R&D



Yang, Ji Hoon, PhD
Managing Director
Biomedical R&D



Kim, Ho Jin, PhD
General Manager
Biomedical R&D

Business Development



Koo, Yong Nam
President
Genomics, Healthcare Platforms, Hair Regeneration



You, Ho Geun
President
Tissue Bank



You, In Hwan
Managing Director
Business Development



Lee, Jong Seung
President
Sales & Business Development



Choi, Moo Geun
PL
Business Development



Lee, Min Goo, MD
General Manager
Business Development

Finance



Kil, Youn Ki, AICPA
CFO
Finance
Chief Financial Officer



Kim, Su Jin
CTO
Human Resources
Chief Talent Officer

Product Development



Choi, Heung Sun
Executive Director
Chief of SCM



Kim, Dae Young
Managing Director
Product Development



Lee, Sang Min
Managing Director
Product Development

Global PI Board



Han, Seung Kyu
Korea University Hospital
Reconstructive Surgery



Dr. Sasikumar, C.
Hycare – India
Wound



Dr. Rajesh Kesavan
Hycare – India
Diabetic Foot



Kook, Kwang Sik
Idea Plastic Surgery
Plastic Surgery



Cetrulo, Curtis L
Massachusetts General Hospital
Plastic Surgery



Prof. V B Narayanamurthy
Hycare – India
Plastic Surgery



Kim, Hae Young
GNG
Plastic Surgery



Song, Seung Yong
Yonsei University Hospital
Plastic Surgery



Dr. Dileck
Acibadem
Bioengeineering



Abdelhamid Mohamad
Assiut Unniversity Hospital



Dr. Arvind Rajagopalan
Hycare Specialty Hospital



Kim, Soo Hwan
Seoul St. Mary's Hospital
ENT



Kim, Do Hyun
Seoul St. Mary's Hospital
ENT



Hwang, Se Hwan
Bucheon St. Mary's Hospital
ENT



Wang, Jun Ho
Samsung Seoul Hospital
Orthopaedics




Ecrument Ovali
Acibadem
GMP Lab Director



Dr. Karaaltın
Private
Plastic Surgery

ROKIT Healthcare 6 Category Kings:



INVIVO Application: Dermatology – DFU Treatment

What is and How bad is Diabetic Foot Ulcer?

- A majority of patients are **Elders**
- Collateral neuropathy and peripheral sense **malfunctioning**
- Average time consumption is at least **14 weeks**
- Complicated foot ulcer takes **infinite period**
- DFU causes critical **economic problems**
- Rising feasibility of death and diminishing quality of live by **cutting feet**



INVIVO Application: Dermatology – DFU Treatment

New Era of Diabetic Foot Ulcer Treatment – Better Survival















Global Clinical Trials – Diabetic Foot Ulcer



0주

환부크기 100%



1주

24%




2주

0%



0주

환부크기 100%




2주

15%



5주

0%



Easier Treatment, Rapid Effect

Organ Regenerator Bioprinter



4D INVIVO

Regulatory Strategy

2019. 5. 26 Approved

EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

London, 26.05.2019
EMA/CAT/191399/2019
Committee for Advanced Therapies (CAT)

SCIENTIFIC RECOMMENDATION ON CLASSIFICATION OF ADVANCED THERAPY MEDICINAL PRODUCTS
Article 17 – Regulation (EC) No 1394/2007

FINAL VERSION

The present scientific recommendation refers exclusively to the case as presented to the Agency without prejudice to future evaluations by the Agency.
It is stressed that the scientific recommendation on advanced therapy classification does not amount to any endorsement of the plausibility of the product, including the mode of action or therapeutic indication(s) claimed by the applicant.

1. CAT OUTCOME SUMMARY		
Proposed product invented name or identifier ("the Product")	MA-ECM film	
EMA product number	EMA/H0005338	
Company developing the Product (applicant)	ROKIT HEALTHCARE, Inc	
Advanced therapy medicinal product classification (as agreed by the CAT)	Not ATMP	X
	Gene therapy medicinal product	
	Somatic cell therapy medicinal product	
	Tissue engineered product	
	Combined ATMP	

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555
Send a question via our website www.ema.europa.eu/contact
An agency of the European Union

© European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged.

4. **Summary for Public Release**

**Information to be extracted from the respective sections of the adopted classification report, redacted to delete commercial confidential information.*

Scientific recommendation on classification of advanced therapy medicinal products

Article 17 – Regulation (EC) No 1394/2007

Disclaimer: This document is a summary for public release of a scientific recommendation on classification of advanced therapy medicinal products. The original text adopted by the Committee for Advanced Therapies (CAT) has been redacted to delete commercially confidential information.

The present scientific recommendation refers exclusively to the case as presented to the European Medicines Agency (EMA) without prejudice to future evaluations by the Agency.

It is stressed that the scientific recommendation on advanced therapy classification does not amount to any endorsement of the plausibility of the product, including the mode of action or therapeutic indication(s) claimed by the applicant.

- **Brief description (or name where available) of the active substance(s)**
- **Brief description of the finished product**
- **Proposed indication**
  - Treatment of scar revision, burn wound, diabetic ulcer, and pressure ulcer

- *Minimal Manipulation*
- *Homologous use*

TECHNOLOGY

4D Biofabricating based

Customized

Autologous

Therapeutic

Solution



Multi-Use Hybrid Bio-4D Printer

INVIVO USER REFERENCES

ROKIT HEALTHCARE

ROKIT

ACADEMIA



SNUH SEOUL NATIONAL UNIVERSITY BUNDANG HOSPITAL

이데아 성형외과 IDEA Plastic Surgery

Massachusetts Eye and Ear HARVARD MEDICAL SCHOOL AFFILIATE

KNUH 경북대학교병원 KYUNGPOOK NATIONAL UNIVERSITY HOSPITAL

Confidential & Proprietary | © ROKIT Healthcare Inc. 2019. All Rights Reserved

Revolutionary Vision

ROKIT HEALTHCARE

Vision

"Aging is Disease"
Upgrade and Expand the life span with our organ regeneration & Healthcare platform

Mission

"Keep Blitz & Simple"
"Solve the organ aging disease problems which others seem to ignore."



Thank You!